This compound is widely used in the field of targeted cancer therapy, particularly in the development of antibody-drug conjugates (ADCs). It serves as a crucial linker-payload component, connecting a cytotoxic agent to a monoclonal antibody. The DBCO group enables efficient and selective conjugation through click chemistry, while the PEG4 spacer enhances solubility and stability. The VC-PAB segment is designed to be cleaved by specific enzymes, such as cathepsin B, which are overexpressed in tumor environments, ensuring the controlled release of the cytotoxic payload at the target site. The MMAE component, a potent antimitotic agent, disrupts microtubule assembly, leading to cancer cell death. This targeted approach minimizes damage to healthy tissues, improving the therapeutic window and reducing side effects compared to traditional chemotherapy.